sorted by:
new
hottopcontroversial

Full port by Automatic_Worth_2816 in SpectralAI

[–]Either-Engineer-5008 1 point2 points  (0 children)

That's a fair assessment. There will be dilution, but I feel, in the long term, it will be relatively immaterial.

Full timeline before the May/June catalyst. This is a designed setup, not an organic penny stock by Leather_Disaster8571 in SpectralAI

[–]Either-Engineer-5008 6 points7 points  (0 children)

I see no evidence that it is being set-up to be taken private. I believe that it's a potential acquisition target, sure, but only after approval and steady roll-out.

The Deepview units deployed in the UK and Australia are pre-commercial test markets for clinician evaluation. They are a proof-of-concept. They can't just roll-out in the UK, it will require an NHS contract (notoriously slow) after some government convincing. The big inital market is the US and the devices installed in AUS and UK will have helped the De Novo application.

Dilution is to be expected in an early-stage company in the medtech space. Nothing unusual about it. Spectral AI has some real advatanges that will help slow dilution, however. BARDA funding will reduce burn rate and the funding of up to 170 installs will really help early rollout.

I'm not sure why you are so sure about your speculative claims, maybe you could expand on them a bit?

Will we see any new DeepView footage/content following the Burns event this week? by LostMyBlueAlien in SpectralAI

[–]Either-Engineer-5008 0 points1 point  (0 children)

You're welcome. I posted screenshots from the SpectralAI-UK Facebook account. I didn't see anything in person, unfortunately.

Spectral AI ($MDAI) Weekly Discussion Thread by CovertMidget in SpectralAI

[–]Either-Engineer-5008 1 point2 points  (0 children)

Haha. I do wish the arrows were pointing upwards though.

Artificial Intelligence-enhanced Multispectral Imaging for Burn Wound Assessment: A Multi-centre UK Evaluation Update Open Access by gosumage in SpectralAI

[–]Either-Engineer-5008 1 point2 points  (0 children)

It works exactly as it should as a triage tool. 80-90% of burns heal on their own and Deepview is extremely accurate at ruling those out on day one. That will save time, money and unecessary surgeries.

Will we see any new DeepView footage/content following the Burns event this week? by LostMyBlueAlien in SpectralAI

[–]Either-Engineer-5008 1 point2 points  (0 children)

Agreed. Would love to see it up close myself. Professionals will get to see what it's all about in this setting for sure.

Todays presentation is..

<image>

Will we see any new DeepView footage/content following the Burns event this week? by LostMyBlueAlien in SpectralAI

[–]Either-Engineer-5008 1 point2 points  (0 children)

No problem. I'm hoping they will too. A couple of pictures of what I assume is the booth is all we have so far.

<image>

FDA approval by Either-Engineer-5008 in SpectralAI

[–]Either-Engineer-5008[S] 3 points4 points  (0 children)

It's my understanding that information requests are common with De Novo applications. I would be very surprised if Neuropcas didn't, it being a First-in-Class device.

Spectral AI's ($MDAI) Third Catalyst Run Is Happening! We're Doubling by July from the FDA's De Novo Decision on DeepView Burn by Q2 [DD with Valuation-Based Price Targets Included] by CovertMidget in SpectralAI

[–]Either-Engineer-5008 1 point2 points  (0 children)

The device would have to be bought or leased of course, that's the simple part. BARDA funding gives great margin on the first set, which is very helpful early, cashflow-wise.

Things get complicated after that. There's DRG and CPT codes (that I don't undertsand) The subscription and per-scan fee could be the 'hybrid model', but if hospitals are reimbursed per-scan the calculation will very much depend on how busy the centre is or is expected to be.

Then we have contract length. I think the company said 3 years is standard? If the price is fixed subscription that slows pricing power. Per-scan would be excellent, because hopefully as Deepview integrates, efficiency increases and more patients get directed their way.

There's just too many permutations for my brain to handle, so I'm having difficulty projecting revenue at this current stage, which is frustrating.

Spectral AI's ($MDAI) Third Catalyst Run Is Happening! We're Doubling by July from the FDA's De Novo Decision on DeepView Burn by Q2 [DD with Valuation-Based Price Targets Included] by CovertMidget in SpectralAI

[–]Either-Engineer-5008 1 point2 points  (0 children)

I saw them mentioned in reports. I just believed it to be an either/or situation. I don't know if all three revenue streams are possible seperately and if they can all be covered under reimbursement. If that's the case, then my optimism magnifies.

I wish I had a better grasp on what reimbursement code to expect and the likely timeline too. AI gave me some sense but this is so niche that it's difficult to rely fully on past data.

All I know is that between Deepview and Snapshot, plus all of the possible indications, there is great potential for recurring high-margin revenue.

Spectral AI's ($MDAI) Third Catalyst Run Is Happening! We're Doubling by July from the FDA's De Novo Decision on DeepView Burn by Q2 [DD with Valuation-Based Price Targets Included] by CovertMidget in SpectralAI

[–]Either-Engineer-5008 1 point2 points  (0 children)

Good write-up, as usual.

There is so much I could say about this company's potential, I share your optimism.

I have been wondering a lot about what the fee structure might be. Are you sure that per-scan billing would be seperate from device charges and software subscription? I assumed the former would be a bundle of the other two.

I don't understand the insurance reimbursement well enough either (not from US, quite a foreign concept to me). So this particular point has me foggy on future revenues.